<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04932525</url>
  </required_header>
  <id_info>
    <org_study_id>2020-A03547-32</org_study_id>
    <secondary_id>2020/3196</secondary_id>
    <nct_id>NCT04932525</nct_id>
  </id_info>
  <brief_title>Gustave Roussy Cancer Profiling</brief_title>
  <acronym>STING</acronym>
  <official_title>Gustave Roussy Cancer Profiling</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of STING study is to perform high throughput molecular analysis (next&#xD;
      generation sequencing +/- immunological profiling) to estimate the proportion of patients&#xD;
      with cancer presenting at least one targetable genomic alteration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STING is a biology driven, multicenter study designed to identify actionable molecular&#xD;
      alterations in cancer patients and to explore mechanisms of sensitivity and resistance to&#xD;
      anti-cancer treatment&#xD;
&#xD;
        -  In this trial, high throughput analysis will be carried out using next generation&#xD;
           sequencing, and immunological profiling&#xD;
&#xD;
        -  Patients included in the STING study and for whom a targetable genomic alteration had&#xD;
           been identified might be subsequently included in a clinical trial running at Gustave&#xD;
           Roussy or another participating center.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 10, 2021</start_date>
  <completion_date type="Anticipated">May 10, 2028</completion_date>
  <primary_completion_date type="Anticipated">May 10, 2028</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The proportion of patients presenting at least one genomic alteration will be estimated in the eligible NGS population and reported using frequency and proportion. The 95% two-sided confidence limits (95%CI) will be provided for the estimated proportion (binomial law). In addition, counts, proportions and 95%CI will be reported for each individual genomic alteration.&#xD;
Survival data will be analysed by standard time-to-event survival techniques.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients presenting at least one targetable genomic alteration</measure>
    <time_frame>2 months after the last enrollment</time_frame>
    <description>Number of patients presenting at least one targetable genomic alteration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>proportion of patients presenting at least one targetable genomic alteration</measure>
    <time_frame>2 months after the last enrollment</time_frame>
    <description>proportion of patients presenting at least one targetable genomic alteration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of molecular profiling information including utilization of information for standard regimens or clinical trials of molecularly targeted therapies</measure>
    <time_frame>2 months after the last enrollment</time_frame>
    <description>For a patient with molecular results available utilization of molecular profiling information is defined as Inclusion in a clinical trial assessing a drug matched to the molecular alteration And/or Treatment with an approved drug matched with the molecular alteration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective response rate</measure>
    <time_frame>24 months post treatment after the last enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>24 months post treatment after the last enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>24 months post treatment after the last enrollment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Solid Tumor, Unspecified, Adult</condition>
  <arm_group>
    <arm_group_label>solid tumor or hematological malignancy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biopsy</intervention_name>
    <description>Blood and tumor samples for Genetic Profiling research</description>
    <arm_group_label>solid tumor or hematological malignancy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age â‰¥ 18 years&#xD;
&#xD;
          2. Histology: solid malignant tumor or hematological malignancy.&#xD;
&#xD;
          3. Patient with a social security in compliance with the French law relating to&#xD;
             biomedical research (Article L.1121-11 of French Public Health Code)&#xD;
&#xD;
          4. Voluntary signed and dated written informed consent prior to any study specific&#xD;
             procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any condition which in the Investigator's opinion makes it undesirable for the subject&#xD;
             to participate in a clinical trial or which would jeopardize compliance with the&#xD;
             protocol&#xD;
&#xD;
          2. Patient under guardianship or deprived of his liberty by a judicial or administrative&#xD;
             decision or incapable of giving its consent&#xD;
&#xD;
          3. Pregnant or breast-feeding women&#xD;
&#xD;
          4. Minors (Age &lt; 18 years)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoine Italiano, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antoine Italiano, MD PhD</last_name>
    <phone>+33 (0)1 42 11 42 11</phone>
    <phone_ext>34 71</phone_ext>
    <email>antoine.italiano@gustaveroussy.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maxime Frelaut, MD</last_name>
    <phone>+33 (0)1 42 11 42 11</phone>
    <email>maxime.frelaut@gustaveroussy.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gustave Roussy Cancer Campus Grand Paris</name>
      <address>
        <city>Villejuif</city>
        <state>Val De Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine Italiano, MD PhD</last_name>
      <phone>+33 (0)1 42 11 42 11</phone>
      <email>antoine.italiano@gustaveroussy.fr</email>
    </contact>
    <contact_backup>
      <last_name>Maxime Frelaut, PhD</last_name>
      <phone>+33 (0)1 42 11 42 11</phone>
      <email>maxime.frelaut@gustaveroussy.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 1, 2021</study_first_submitted>
  <study_first_submitted_qc>June 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2021</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immunological profiling</keyword>
  <keyword>targetable oncogenic aberration</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

